Key Words: SurePath. CINtec; p16; Ki-67, MIB1; sensitivity; specificity;
|
|
- Charlene Johnston
- 6 years ago
- Views:
Transcription
1 Evaluation of CINtec PLUS 1 Testing as an Adjunctive Test in ASC-US Diagnosed Surepath 1 Preparations Neil Edgerton, M.D., Cynthia Cohen, M.D., andmomint. Siddiqui,M.D., F.I.A.C.* The CINtec PLUS 1 system is an immunohistochemical cocktail composed of antibodies against p16 INK4a (surrogate of HPV infection) and Ki-67 (proliferation marker) meant to improve the sensitivity and specificity for detecting high-grade dysplasia (HGD). In the presence of dysplasia, a red chromogen marks Ki-67 expression in the nucleus and a brown chromogen marks cytoplasmic p16 INK4a expression. Only cells showing dual staining are interpreted as positive. This retrospective study examined the performance of CINtec PLUS testing when performed on ASC-US diagnosed samples. Comparison was made to highrisk HPV DNA test results and colposcopic biopsy results. Technical considerations in the interpretation of this immunohistochemical stain are additionally discussed. CINtec PLUS showed modest sensitivity (64%) and specificity (53%) in identifying the presence of HGD at surgical biopsy. Positive and negative predictive values for HGD were 28% and 83%, respectively. HR- HPV DNA test yielded sensitivity of 100% and specificity of 21%. During interpretation, squamous metaplasia and endocervical cells were seen to show individual staining for p16 INK4a or Ki-67. Individual staining, when present within three dimensional cellular groups common to SurePath 1 preparations, can be time-intensive to interpret necessitating thoughtful examination at high power. The Pap test with HR-HPV DNA testing is a highly sensitive test. A specific test is needed to prevent false positives and over treatment. The CINtec 1 system provides a modest increase in specificity beyond HR-HPV DNA testing. Future study of its appropriateness and cost-ffectiveness in a treatment algorithm are warranted. Diagn. Cytopathol. 2013;41: ' 2011 Wiley Periodicals, Inc. Key Words: SurePath CINtec; p16; Ki-67, MIB1; sensitivity; specificity; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia *Correspondence to: Momin T. Siddiqui, M.D., F.I.A.C., Department of Pathology, Room G179B, Emory University Hospital, 1364 Clifton Rd. NE, Atlanta, GA mtsiddi@emory.edu Received 21 March 2011; Accepted 11 May 2011 DOI /dc Published online 27 June 2011 in Wiley Online Library (wileyonlinelibrary.com). The 2001 Bethesda Conference standardized diagnostic terminology within the field of cervical cytopathology. 1 This standardization, in turn, allowed for well developed treatment algorithms to detect and treat cervical dysplasia and carcinoma. 2 Where cervical cancer was once the most common carcinoma to affect women, it now numbers thirteenth in the United States. 3 In 1950, the rate of cervical cancer within the US was 26.2 per 100, By 2006, the rate had fallen to 5.2 per 100, The widespread use of Pap testing is a public health success. As proof of this in 2008, nearly 88% of women aged had received an annual cervical cancer screening thus demonstrating the acceptance of this test by practitioner and patient alike. 5 The broad adoption of HR-HPV testing has furthered the role of the Pap test. The use of this ancillary test on residual sampled material allows for the extremely high sensitivity expected of a screening test. Further, HPV testing provides another means of stratifying risk within the treatment algorithms. 2,6 Given such success, efforts are now turning to increasing the specificity of the Pap test. Effort is being directed at identifying the subset of women who harbor high-grade dysplasia (HGD) within those Pap tests diagnosed as atypical squamous cells of undetermined significance (ASCUS) or low grade squamous intraepithelial lesion (LSIL). Human papilloma virus drives dysplastic changes that ultimately lead to carcinoma. The progression of disease is long and numbers in years. 7 In the majority of cases, viral infection is transient in nature. 8,9 Only a small set of patients progress to higher grades of dysplasia. Some of these patients will still undergo spontaneous regression of dysplasia without the development of carcinoma. 10 Carcinoma represents an accumulation of insults to the cervical squamous mucosa in which the HPV virus has integrated into the host DNA due to the inability of the immune system to clear the virus. This specific progression occurs via the direct action of two viral oncoproteins E6 and E7. ' 2011 WILEY PERIODICALS, INC. Diagnostic Cytopathology, Vol 41, No 1 35
2 EDGERTON ET AL. The oncoprotein E6 interacts with host p53 tumor suppressor protein resulting in degradation of p53 thus preventing apoptotic death of the cell. 11 The oncoprotein E7 interacts with host retinoblastoma protein, such that when Rb protein is bound, it is unavailable to halt the cell cycle. 12 Ultimately, the disabling of these two proteins allows for unhindered cellular proliferation. p16 INK4a, is a cyclin-dependent kinase inhibitor, that serves to negatively regulate cellular proliferation. 13 Its expression is upregulated in viral integration; thus, immunohistochemical staining for p16 INK4a is a surrogate marker of HPV infection. Active cellular proliferation is identified by nuclear expression of Ki-67. Ki-67 is an antigen that is present during cellular proliferation, specifically late G1 and S phases. 14 The CINtec PLUS 1 system is an immunohistochemical cocktail composed of antibodies against p16 INK4a and Ki-67 meant to improve the detection of HGD. Specifically, it has been examined as an adjunctive test that would serve to increase overall specificity. 15 In the presence of dysplasia, a red chromogen marks Ki-67 expression in the nucleus and a brown chromogen marks cytoplasmic p16 INK4a expression. This retrospective study examined the performance characteristics of CINtec PLUS testing when performed on ASC- US diagnosed samples prepared in SurePath preparations. Materials and Methods Patients and specimens A total of 63 SurePath 1 Pap test slides diagnosed as ASC-US with correlative colposcopic biopsy were identified over a 17 month period from Emory University Hospital. Correlative colposcopic biopsy diagnoses were derived from the medical record. Follow-up biopsy results represent biopsies diagnosed by the routine staff physicians within our institution, and were secondarily reviewed as part of the institution s QA/QC program. In the event multiple biopsies were taken, the most severe dysplasia (highest CIN) was recorded. Digene Hybrid Capture 1 II HPV DNA test (Digene Corporation, Gaithersburg, MD) was performed on Sure- Path specimens at ARUP Laboratories (Salt Lake City, Utah). The samples were received within one day of collection and stored at room temperature until testing was performed within 2 week of specimen collection. Digene Hybrid Capture 1 II HPV DNA testing was performed according to the manufacturer s recommendations using the high-risk probes with the positive and negative control samples run in triplicate and result validation using HC2 software, version 2.0. The high-risk HPV panel consisted of 13 types of HPV (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68). The hybridized product is detected by chemiluminescent reporter system. The test results are given as relative light unit ratios. The manufacturer has set a positive cut-off value of 1 pg HPV DNA per ml in the specimen. Immunohistochemistry was performed on previously prepared SurePath Papanicolaou stained slides (Becton, Dickinson and Company, Franklin Lakes, NJ), which were destained according to manufacturer provided protocol. SurePath slides were incubated overnight in xylene to remove the coverslips. A secondary wash with fresh xylene removed residual mounting medium. Progressive rehydration from ethanol to deionized water was performed. Antigen retrieval was performed with the proprietary Epitope Retrieval Solution provided within the CINtec Cytology Kit (mtm Laboratories, Heidelberg, Germany). Retrieval was carried out within a water bath where the temperature was raised from room temperature to C within 40 minutes. Once at 958C, the slides were incubated for 15 minutes. Slides were cooled for 20 minutes within the Epitope Retrieval Solution. Slides were then placed in wash buffer (Tris-buffered saline) for 5 minutes prior to immunostaining. All slides were loaded on an automated system (Dako AutoStainer plus, Carpinteria, CA) and incubated with primary antibodies per the provided CINtec PLUS Kit protocol. Slides were then counterstained with hematoxylin for 5 minutes. The slides were then air-dried and 40 ll of CINtec PLUS Mount aqueous mounting medium was swirled over the specimen. The aqueous mounting medium was allowed to dry before placing slides in xylene for 1 minute, and manual coverslipping with xylene based mounting medium. A positive control was derived from a SurePath slide diagnosed as HSIL and confirmed CIN III by biopsy. A negative control was derived from a SurePath slide diagnosed as negative for intraepithelial lesion or malignancy. Analysis Slides were analyzed by a single pathologist without adjudication. The pathologist knew the sample was composed of ASC-US diagnosed cytology specimens, but was blinded to the specific cytology diagnosis, HR-HPV results, and surgical biopsy findings. The slides were interpreted as positive or negative for CINtec PLUS staining based on manufacturer provided atlas and guidelines. In the presence of dysplasia, a red chromogen marked Ki-67 expression in the nucleus and a brown chromogen marked cytoplasmic p16 INK4a expression. Classically, immunohistochemical staining for p16 INK4a is nuclear and cytoplasmic. In this double stain, p16 INK4a nuclear staining is obscured by the intense red chromogen that marks Ki-67. The testing was considered positive if a minimum of one cell showed simultaneous dual staining (Figs. 1a and b). The utility of CINtec staining on SurePath slides was determined using sensitivity and specificity calcula- 36 Diagnostic Cytopathology, Vol 41, No 1
3 CINtec PLUS SENSITIVITY AND SPECIFICITY Fig. 1. a: Dysplastic cell interpreted as positive for CINtec staining exhibits nuclear Ki-67 (red chromogen) and cytoplasmic p16 (brown chromogen), 340. b: Cell on top with cytoplasmic and nuclear p16 interpreted as negative. Cell on bottom interpreted as positive, exhibits nuclear Ki-67 and cytoplasmic p16, 360. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] Table I. Correlative Results Biopsy Cytology NILM CIN I CINII CIN III ASC-US (n ¼ 3) tions performed by the JavaSTAT online contingency table calculator. Results Within our sample set, 44% of atypical squamous cell diagnoses were found to have a CIN lesion (CIN I III) (Table I). Fourteen cases (22%) of our sample set of ASC-US cases had HGD (CIN II/III) at the time of cervical biopsy. No cases of cervical carcinoma were present. Staining with the CINtec PLUS system has modest sensitivity (64%) and specificity (53%) in identifying the presence of HGD at surgical biopsy (Table II). Positive and negative predictive values for HGD were 28% and 84%, respectively (Table II). HR-HPV DNA testing yielded a sensitivity of 100% and specificity of 21% (Table III). The data for HR-HPV testing are derived from a small sample, but do show it to be a sensitive test for disease exclusion. Results of CINtec Plus interpretation on Pap slides were sorted by diagnosis at the time of colposcopic biopsy (Table IV). Since the ultimate goal of this test is risk stratification, we assume that the gains in specificity are achieved by demonstrating morphologic changes seen within the Pap test as the result of HPV infection (proved by p16 and Ki-67 expression), and that these changes are driven by the presence of HPV (proved by HR-HPV DNA testing). These two independent tests are thus interpreted in series, whereby both tests must be positive to give a higher level of risk. This performance of two tests in series increases Table II. CINtec PLUS Staining Sensitivity and Specificity in Detecting HSIL (CIN II/III) Sensitivity 64% Specificity 53% PPV 28% NPV 84% PPV, positive predictive value; NPV, negative predictive value. Table III. HR-HPVDNA Testing Sensitivity and Specificity in Detecting HSIL (CIN II/III) Sensitivity 100% Specificity 21% PPV 50% NPV 100% PPV, positive predictive value; NPV, negative predictive value. Table IV. CINtec PLUS 1 Stain Interpretation Within Pap Slides Compared by Final Biopsy Diagnosis specificity. The overall specificity or net specificity of these two tests is computed by summing the specificity of the two tests minus the product of the two test s specificity (A+B) (A 3 B). The overall specificity, in this Diagnostic Cytopathology, Vol 41, No 1 37
4 EDGERTON ET AL. Fig. 2. Squamous metaplasia recognized by sharp cytoplasmic border, exhibiting diffuse p16 staining (brown chromogen), 340. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] study, of interpreting a case that stained positive with the CINtec PLUS system and was also HR-HPV DNA positive was found to be 63%. Discussion In this study, we document our experience with the CINtec PLUS immunohistochemical protocol. Knowing that significant interobserver variability exists in the atypical squamous cell categories, we explored the performance of the CINtec PLUS immunohistochemical staining protocol and its ability to identify HGD. The value of p16 in the analysis of cervical biopsy has been reliably demonstrated. Evaluation with p16 immunohistochemical staining is shown to be as effective as an expert consultation in resolving difficult cases. 16 Likewise, the introduction of p16 into routine staining of punch and cone biopsy specimens leads to higher interobserver agreement. 17 There is a movement to utilize p16 testing and Ki-67 staining on cytological material for the purpose of increasing interobserver agreement and to stratify patients for treatment purposes. 18 Numerous studies have examined p16 immunohistochemical staining performed on cytology specimens with a wide disparity in results (reviewed by Tsoumpou et al. 19 ). In the largest multicenter study to date, sensitivity and specificity as high as 95.1% and 71.1%, respectively, were reported for detecting HGD among ASCUS cytology specimens. 20 It should be noted that those numbers represent a process of adjudication in which discrepant cases are secondarily reviewed and reinterpreted in a group setting or with cytotechnologists, individual pathologist interpretation yielded lower sensitivity and specificity. While there is a range of sensitivity and specificity between studies to date, within individual studies the performance characteristics so far seem Fig. 3. Endocervical cells showing sporadic Ki-67 expression (red chromogen), 360. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] independent of age. 21 Efforts have been made to stratify risk based on the percentage of positively staining cells. 22 There are some technical considerations of note in the interpretation of the CINtec PLUS immunohistochemical stain that are worthy of mention. First, the interpretation of a positive result requires a nucleus stained with a red chromogen and a cytoplasm stained with brown chromogen. The background stain is hematoxylin. Others have rightly noted that the hematoxylin counterstain is different from the Papanicolaou stain. 23 We agree with the assertion that there is a subtle difference in the chromatin appearance, likely due to different bluing procedures among different hematoxylins. Second, interpretation is not a matter of positive or negative (the case in the majority of surgical pathology immunohistochemistry); rather, thoughtful evaluation of cell morphology is required to exclude squamous metaplasia, tubal metaplasia, and endocervical cells that may stain individually for p16 or Ki-67. Cells with rigid cell borders easily recognized as squamous metaplasia may show p16 positivity (Fig. 2). Groups of endocervical cells inherently show focal positive staining for Ki-67 (Fig. 3). These patterns are noted by the manufacturer, and are not to be interpreted as positive. Only dual staining cells, marked by brown and red chromogens, are to be interpreted as positive. Thus, interpretation of this immunostain requires the examiner to frequently turn to higher power to exclude normal cells that stain for an individual chromogen only. For those specimens with abundant metaplasia or a significant endocervical component, it was time consuming to 38 Diagnostic Cytopathology, Vol 41, No 1
5 CINtec PLUS SENSITIVITY AND SPECIFICITY Fig. 4. Acute inflammation expressing Ki-67 (red chromogen), 340. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] find the rare atypical cell that had been readily identified on Papanicolaou test. On one such slide, at its extreme, it took some 8 min to interpret the immunohistochemical stain. Scoring systems have been proposed and evaluated to assure that positive staining is only assessed within dysplastic cells. 21,24 In addition, acute inflammation frequently showed Ki-67 nuclear expression, causing the microscopic field of view to be filled with red chromogen reactivity (Fig. 4). Finally, the interpretation of CINtec PLUS system on SurePath specimens may have some added difficulties. Previous studies have been carried out predominantly on ThinPrep 1 preparations which have a larger button, more widely spaced cells, and are a true monolayer. SurePath slides with their smaller button have a tendency toward more three dimensional groups. The three dimensionality is present in both squamous and endocervical cells. These three dimensional clusters obscured stained cells and hindered interpretation necessitating high power examination across multiple focal planes to resolve the location (cytoplasmic or nuclear) and character (individual or dual) of staining (Figs. 5a and b). The sensitivity and specificity of CINtec PLUS seen in our study are lower than that demonstrated by other studies that have utilized a process of adjudication, but our results are roughly comparable to individual pathologist interpretation without adjudication within those same studies. Overall, the combined specificity gained by the performance of CINtec PLUS and HR-HPV testing is an improvement over current practice. The increased specificity of this test, besides simply creating another triage option, could conceivably lead to a reduction in colposcopic procedures. HR-HPV testing has been found to be a cost-effective ancillary test in analysis performed on data derived from the ALTS trial. 25 Fig. 5. a: Three dimensional cluster of endocervical cells common to SurePath preparations. Only individual staining of Ki-67 is present. Though this would be interpreted as negative, the three dimensional nature of the cluster could conceivably obscure dysplastic cells, 340. b: Three dimensional clusters of squamous cells common to SurePath preparations. These clusters may pose difficulties in interpreting the dual cytoplasmic and nuclear features of the immunohistochemical stain, 360. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] The cost-effectiveness of the CINtec PLUS system has yet to be demonstrated within the literature. Our study is far too small for such an analysis. However, it is clear that there would be an immediate procedural charge for immunohistochemical staining performed on a liquidbased preparation. The cost benefit of this ancillary test lies in avoiding colposcopy which requires both an evaluation and management charge for the patient s office visit along with the associated procedural cost of colposcopy with or without biopsy. Though more difficult to calculate, the time and discomfort of the patient is saved, is the biggest argument for increasing specificity. In conclusion, our study, though admittedly small, demonstrates an improvement in specificity above HR-HPV testing alone, and also reviews some potential difficulties Diagnostic Cytopathology, Vol 41, No 1 39
6 EDGERTON ET AL. encountered in the interpretation of this immunohistochemical stain. References 1. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287: Wright TC, Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197: Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, , featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116: Rust G, Satcher D, Fryer GE, Levine RS, Blumenthal DS. Triangulating on success: Innovation, public health, medical care, and cause-specific US mortality rates over a half century ( ). Am J Public Health 2010;100 (Suppl 1):S95 S Henley SJ, King JB, German RR, Richardson LC, Plescia M. Surveillance of screening-detected cancers (colon and rectum, breast, and cervix) United States, MMWR Surveill Summ 2010;59: Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: Realistic estimates from the ASCUS-LSIL Triage Study, JAMA 2001;285: van Oortmarssen GJ, Habbema JD. Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative pap smears. Int J Epidemiol 1995;24: Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180: Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338: Nasiell K, Nasiell M, Vaclavinkova V. Behavior of moderate cervical dysplasia during long-term follow-up. Obstet Gynecol 1983;61: Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001;20: Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989;63: Khleif SN, DeGregori J, Yee CL, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA 1996;93: Key G, Becker MH, Baron B, et al. New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cdna containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 1993;68: Reuschenbach M, Clad A, von Knebel Doeberitz C, et al. Performance of p16ink4a-cytology. HPV mrna, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results, Gynecol Oncol 2010;119: Dijkstra MG, Heideman DA, de Roy SC, et al. p16(ink4a) immunostaining as an alternative to histology review for reliable grading of cervical intraepithelial lesions. J Clin Pathol 2010;63: Bergeron C, Ordi J, Schmidt D, Trunk MJ, Keller T, Ridder R. Conjunctive p16ink4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol 2010;133: Wentzensen N, Bergeron C, Cas F, Vinokurova S, von Knebel Doeberitz M. Triage of women with ASCUS and LSIL cytology: Use of qualitative assessment of p16ink4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. Cancer 2007;111: Tsoumpou I, Arbyn M, Kyrgiou M, et al. p16(ink4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009;35: Denton KJ, Bergeron C, Klement P, Trunk MJ, Keller T, Ridder R. The sensitivity and specificity of p16(ink4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results. Am J Clin Pathol 2010; 134: Szarewski A, Ambroisine L, Cadman L, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008;17: Carozzi F, Confortini M, Dalla Palma P, et al. Use of p16-ink4a overexpression to increase the specificity of human papillomavirus testing: A nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008;9: Meyer JL, Hanlon DW, Andersen BT, Rasmussen OF, Bisgaard K. Evaluation of p16ink4a expression in ThinPrep cervical specimens with the CINtec p16ink4a assay: Correlation with biopsy followup results. Cancer 2007;111: Wentzensen N, Bergeron C, Cas F, Eschenbach D, Vinokurova S, von Knebel Doeberitz M. Evaluation of a nuclear score for p16ink4a-stained cervical squamous cells in liquid-based cytology samples. Cancer 2005;105: Kulasingam SL, Kim JJ, Lawrence WF, et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst 2006;98: Diagnostic Cytopathology, Vol 41, No 1
Detecting High-Grade Cervical Disease on ASC-H Cytology. Role of BD ProEx C and Digene Hybrid Capture II HPV DNA Testing
Anatomic Pathology / BD ProEx C Use in ASC-H Cy t o l o g y Detecting High-Grade Cervical Disease on ASC-H Cytology Role of BD ProEx C and Digene Hybrid Capture II HPV DNA Testing Momin T. Siddiqui, MD,
More informationP16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future.
P16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future. Mark H Stoler, MD University of Virginia Health System, Charlottesville, VA,
More informationUsefulness of p16/ki67 Immunostaining in the Triage of Women Referred to Colposcopy
Usefulness of p16/ki67 Immunostaining in the Triage of Women Referred to Colposcopy Jaume Ordi, MD, PhD 1 ; Amaia Sagasta, MD 1 ; Meritxell Munmany, MD 2 ; Leonardo Rodrıguez-Carunchio, MD 1 ; Aureli Torne,
More informationAbstract. Anatomic Pathology / p16 Cytology for ASC-US and LSIL Triage
Anatomic Pathology / p16 Cytology for ASC-US and LSIL Triage The Sensitivity and Specificity of p16 INK4a Cytology vs HPV Testing for Detecting High-Grade Cervical Disease in the Triage of ASC-US and LSIL
More informationTable of Contents. 1. Overview. 2. Interpretation Guide. 3. Staining Gallery Cases Negative for CINtec PLUS
Staining Atlas Table of Contents 1. Overview 1.1 Introduction 1.2 Role of p16 INK4a 1.3 Role of Ki-67 1.4 Molecular Pathogenesis 1.5 p16 INK4a Expression in Cervical Dysplasia 1.6 The Concept of CINtec
More informationHPV Testing & Cervical Cancer Screening:
HPV Testing & Cervical Cancer Screening: Are they linked? By William Chapman, MD, FRCPC Screening for precursor lesions of cervical cancer by the Papanicolaou (Pap) smear has been one of the greatest success
More informationInterpretation guide. Abnormal cytology can t hide anymore
Interpretation guide Abnormal cytology can t hide anymore Unique dual-biomarker technology makes you certain about the presence of transforming HPV infection. The science that creates certainty. Table
More informationCINtec PLUS and the Pap smear: a co-testing alternative
CINtec PLUS and the Pap smear: a co-testing alternative Rosemary Tambouret MD p16/ki67 (CINtec PLUS) and the Pap smear Rosemary Tambouret MD CINtec PLUS dual stain: p16 and Ki67 p16 is anti-proliferative
More informationWelcome. THE ROLE OF oncofish cervical ASSESSMENT OF CERVICAL DYSPLASIA. March 26, 2013
THE ROLE OF oncofish cervical IN THE ASSESSMENT OF CERVICAL DYSPLASIA The phone lines will open, 15 minutes prior to the start of the webinar. Toll Free: 1-800-867-0864. Entry Code: 83956484. You may download
More informationCan HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation?
Anatomic Pathology / Monitoring HPV-16 Fractions in CIN Can HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation? Mary T. Galgano, MD, 1 Philip E. Castle, PhD, MPH, 2 Mark
More informationPushing the Boundaries of the Lab Diagnosis in Asia
Pushing the Boundaries of the Lab Diagnosis in Asia Diana Lim MBBS, FRCPA, FRCPath (UK) Senior Consultant National University Health System and National University of Singapore Department of Pathology
More informationP16 INK4A EXPRESSION AS A POTENTIAL PROGNOSTIC MARKER IN CERVICAL PRECANCEROUS AND CANCEROUS LESIONS IN MOROCCO
P16 INK4A EXPRESSION AS A POTENTIAL PROGNOSTIC MARKER IN CERVICAL PRECANCEROUS AND CANCEROUS LESIONS IN MOROCCO Yassine Zouheir Laboratory of histo-cytopathology of Institut Pasteur of Morocco, Casablanca,
More informationNegative Colposcopic Biopsy After Positive Human Papilloma Virus (HPV) DNA Testing False-Positive HPV Results or False-Negative Histologic Findings?
Anatomic Pathology / FALSE-NEGATIVE HISTOLOGIC FINDINGS Negative Colposcopic Biopsy After Positive Human Papilloma Virus (HPV) DNA Testing False-Positive HPV Results or False-Negative Histologic Findings?
More informationMolecular Analysis in the Diagnosis and Management of Lesions of Uterine Cervix: The 95% solution. Mark H. Stoler, MD PSC Symposium USCAP 2008
Molecular Analysis in the Diagnosis and Management of Lesions of Uterine Cervix: The 95% solution Mark H. Stoler, MD PSC Symposium USCAP 2008 Objectives: This presentation will briefly review the currently
More informationHPV Genotyping: A New Dimension in Cervical Cancer Screening Tests
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests Lee P. Shulman MD The Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief, Division of Clinical Genetics Feinberg School
More informationThe LAST Guidelines in Clinical Practice. Implementing Recommendations for p16 Use
AJCP / Original Article The LAST Guidelines in Clinical Practice Implementing Recommendations for p16 Use Lani K. Clinton, MD, PhD, 1,2 Kyle Miyazaki, 1 Asia Ayabe, 1 James Davis, PhD, 2 Pamela Tauchi-Nishi,
More informationBeyond Pap Morphological Triage: p16/ki67 Dual Staining
Moving away from Beyond Pap Morphological Triage: p16/ki67 Dual Staining Nicolas Wentzensen MD, PhD, MS Deputy Chief, Clinical Genetics Branch; Head, Clinical Epidemiology Unit National Cancer Institute
More informationComparative study of human papilloma virus DNA detection and results of histopathological examination of cervical colposcopic biopsy
Iranian Journal of Reproductive Medicine Vol.5. No.3. pp:121-126, Summer 2007 Comparative study of human papilloma virus DNA detection and results of histopathological examination of cervical colposcopic
More informationLessons From Cases of Screened Women Who Developed Cervical Carcinoma
Lessons From Cases of Screened Women Who Developed Cervical Carcinoma R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center raustin@magee.edu Why Focus Study On Cases
More informationHuman Papillomavirus Testing Using Hybrid Capture II With SurePath Collection
468 Human Papillomavirus Testing Using Hybrid Capture II With SurePath Collection Initial Evaluation and Longitudinal Data Provide Clinical Validation for This Method Vincent Ko, MD Rosemary H. Tambouret,
More informationCINtec PLUS Cytology. Interpretation training
CINtec PLUS Cytology Interpretation training Objectives After reviewing this learning module, you will have a basic understanding of how to interpret CINtec PLUS Cytology, including: The mechanism of action
More informationAbnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing
280 Abnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing Giovanni Negri, MD Bettina Rigo, BS Fabio Vittadello, ScD Christine Mian, ScD Eduard Egarter-Vigl, MD Department of Pathology,
More informationA Cytologic/Histologic Review of 367 Cases. Original Article. Cancer Cytopathology August 25,
Correlation Between Hybrid Capture II High-Risk Human Papillomavirus DNA Test Chemiluminescence Intensity From Cervical Samples With Follow-Up Histologic Results A Cytologic/Histologic Review of 367 Cases
More informationchapter 4. The effect of oncogenic HPV on transformation zone epithelium
chapter 4. The effect of oncogenic HPV on transformation zone epithelium CHAPTER 1 All squamous cervical cancer (and probably all cervical adenocarcinoma) is associated with oncogenic HPV, and the absence
More informationCytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches.
Cytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches. Fadi W. Abdul-Karim MD MEd. Professor of Pathology. Vice chair for education. Robert Tomsich Pathology and Lab Med
More informationNews. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM
Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND
More informationAtypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing
Anatomic Pathology / ATYPICAL GLANDULAR CELLS AND HUMAN PAPILLOMAVIRUS Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing Jeffrey F. Krane,
More informationOutcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure
The Korean Journal of Pathology 2012; 46: 359-364 ORIGINAL ARTICLE Outcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure Joon Seon Song Ilseon
More informationEvaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions on Cervical Smear
The Korean Journal of Pathology 2010; 44: 528-35 DOI: 10.4132/KoreanJPathol.2010.44.5.528 Evaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions
More informationp16ink4a expression in cervical intraepithelial neoplasia and cervical cancer
Original Article Brunei Int Med J. 2013; 9 (3): 165-171 p16ink4a expression in cervical intraepithelial neoplasia and cervical cancer Kalpana KUMARI 1 and Akhila Arcot VADIVELAN 2 1 Department of Pathology,
More informationCervical cancer prevention: Advances in primary screening and triage system
Cervical cancer prevention: Advances in primary screening and triage system Dr Farid Hadi Regional Medical and Scientific Affairs Roche Diagnostics Asia-Pacific, Singapore Cervical cancer is highly preventable
More informationVasile Goldiş Western University of Arad, Faculty of Medicine, Obstetrics- Gynecology Department, Romania b
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Cervical Intraepithelial Neoplasia in the Dr. Salvator Vuia Clinical Obstetrics and Gynecology Hospital - Arad During the 2000-2009 Period Voicu
More informationNILM Pap Slides From Women 30 Years of Age and Older With Positive High-Risk HPV DNA
NILM Pap Slides From Women 30 Years of Age and Older With Positive High-Risk HPV DNA Focused Rescreening Prior to Report Issuance, An Enhanced Quality Control Measure Karen Cormier, CT(ASCP), 1 Michael
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.16.6857 Cost-Effectiveness of Strategies for Detection CIN2+ in Women with ASC-US Pap Smears in Thailand RESEARCH ARTICLE Cost-Effectiveness Analysis of Different
More informationAtypical squamous cells. The case for HPV testing
OBG MANAGEMENT FOCUS ON CERVICAL DISEASE BY J. THOMAS COX, MD ASC-US is most often due to transient changes or HPV. HPV-positive ASC-US is 12.5 to 23 times more likely to be associated with CIN 2,3 on
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationThe devil is in the details
The cobas KNOW THE RISK For cervical cancer prevention The devil is in the details Leading with the cobas as your primary screening method uncovers disease missed by cytology, and can protect women from
More informationp16 Cervical HISTOLOGY Histology Compendium & Staining Atlas
p16 Cervical HISTOLOGY Histology Compendium & Staining Atlas Chapter 1: An Introduction to p16...... 3 Normal Cervical Epithelium and the Cell Cycle....4 HPV Infection and Cervical Disease......................................
More informationPerformance of the Aptima High-Risk Human Papillomavirus mrna Assay in a Referral Population in Comparison with Hybrid Capture 2 and Cytology
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2011, p. 1071 1076 Vol. 49, No. 3 0095-1137/11/$12.00 doi:10.1128/jcm.01674-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Performance
More informationFaculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
More informationARTICLE IN PRESS. is not an effective triage test for women. women with high-grade squamous intraepithelial
Research ONCOLOGY Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding G. Reza Jalali, PhD; Thomas J. Herzog, MD; Bruce
More informationOriginal Policy Date
MP 2.04.03 Cervicography Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index Disclaimer
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationObjectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies
Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives
More informationGynecologic Oncology
Gynecologic Oncology 121 (2011) 505 509 Contents lists available at ScienceDirect Gynecologic Oncology journal homepage: www.elsevier.com/locate/ygyno Triaging Pap cytology negative, HPV positive cervical
More informationCINtec p16 INK4a Staining Atlas
CINtec p16 INK4a Staining Atlas Rating Rating Positive The rating positive will be assigned if the p16 INK4a -stained slide shows a continuous staining of cells of the basal and parabasal cell layers of
More informationCAP Laboratory Improvement Programs
CAP Laboratory Improvement Programs Practices of Participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology, 2006 Galen M. Eversole, MD; Ann T. Moriarty,
More informationPAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE
Arch Iranian Med 2005; 8 (3): 192 196 Original Article PAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Fatemeh Ghaemmaghami MD *, Fereshteh Ensani MD**, Nadereh Behtash MD* Ebrahim
More informationUtilization of the Biomarkers to Improve Cervical Cancer Screening
Utilization of the Biomarkers to Improve Cervical Cancer Screening Elena BERNAD Victor Babes University of Medicine and Pharmacy Timisoara, Romania Cervical cancer is at the second most common cancer in
More informationCK17 and p16 expression patterns distinguish (atypical) immature squamous metaplasia from high-grade cervical intraepithelial neoplasia (CIN III)
Histopathology 2007, 50, 629 635. DOI: 10.1111/j.1365-2559.2007.02652.x CK17 and p16 expression patterns distinguish (atypical) immature squamous metaplasia from high-grade cervical intraepithelial neoplasia
More informationCytology Report Format
Squamous Precursor Lesions and Malignancies In Pap Test Dina R. Mody, MD, FCAP Director of Cytology The Methodist Hospital, Houston, TX Professor of Pathology and Laboratory Medicine Weill Medical College
More informationBiomed Environ Sci, 2015; 28(1): 80-84
80 Biomed Environ Sci, 2015; 28(1): 80-84 Letter to the Editor Assessing the Effectiveness of a Cervical Cancer Screening Program in a Hospital-based Study* YANG Yi1, LANG Jing He1, WANG You Fang1, CHENG
More informationThe Korean Journal of Cytopathology 13(1): 14-20, 2002
13 1 The Korean Journal of Cytopathology 13(1): 14-20, 2002 : ASCUS 1941 Papanicolaou. The Bethesda System(TBS) 1) 1988, atypical squamous cells of undetermined significance(ascus), low-grade squamous
More informationCME/SAM. Follow-up Outcomes in a Large Cohort of Patients With Human Papillomavirus Negative ASC-H Cervical Screening Test Results
Anatomic Pathology / HPV-Negative ASC-H Follow-up Outcomes in a Large Cohort of Patients With Human Papillomavirus Negative ASC-H Cervical Screening Test Results David Cohen, MD, R. Marshall Austin, MD,
More informationHPV TESTING AND UNDERSTANDING VALIDITY: A tough row to hoe. Mark H. Stoler, MD ASC Companion Meeting USCAP 2008
OBJECTIVES: HPV TESTING AND UNDERSTANDING VALIDITY: A tough row to hoe Mark H. Stoler, MD ASC Companion Meeting USCAP 2008 1. Describe the concept of marker validation in the context of HPV tests. 2. Present
More informationIt depends on the site: In Cervix 99%, in Anus ~ 85-90% and in Vulva, Penis ~ 40-50%. True.
Are all high grade lesions caused by HPV, or are there other etiologies? The issue is not if you are infected with HPV high risk, but which of the patients infected with HR hpv would go into progressive
More informationAcceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index
DOI 10.1007/s00404-012-2569-y GYNECOLOGIC ONCOLOGY Acceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index Hadi Shojaei Fariba Yarandi Leila
More informationOver-diagnoses in Cytopathology: Is histology the gold standard?
Over-diagnoses in Cytopathology: Is histology the gold standard? Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Faculty Disclosures: Teresa M. Darragh,
More informationCME/SAM. High-Risk HPV Testing in Women 30 Years or Older With Negative Papanicolaou Tests Initial Clinical Experience With 18-Month Follow-up
Anatomic Pathology / HPV Testing in Negative Papanicolaou Tests High-Risk HPV Testing in Women 30 Years or Older With Negative Papanicolaou Tests Initial Clinical Experience With 18-Month Follow-up Michael
More informationCervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients
Cervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients Richard Hopley, MD, Alexandra Gillespie, MD* Laboratory Medicine 47:1:52-56 CLINICAL HISTORY Patients:
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationBiomarkers and HPV testing: The future of cervical screening
THE FUTURE OF CERVICAL SCREENING Earn 3 CPD Points online Biomarkers and HPV testing: The future of cervical screening Professor John O Leary Associate Professor and Director of Pathology Coombe Women
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent
More informationChapter 14: Role of Triage Testing in Cervical Cancer Screening
Chapter 14: Role of Triage Testing in Cervical Cancer Screening Diane Solomon The classic model of cervical cancer prevention primary screening with cytology, followed by diagnostic colposcopically directed
More informationQuantitative Optical Spectroscopy of the Uterine Cervix: A cost effective way to detect and manage cervical disease
Quantitative Optical Spectroscopy of the Uterine Cervix: A cost effective way to detect and manage cervical disease Nahida Chakhtoura, MD, Leo Twiggs, MD, Timothy DeSantis, MD Claudia Werner, MD, William
More informationEfficacy evaluation of a test CINtec p16ink4a in screening for cervical HPV infection
Vol.1, No.3, 154-163 (2011) doi:10.4236/ojpm.2011.13020 Open Journal of Preventive Medicine Efficacy evaluation of a test CINtec p16ink4a in screening for cervical HPV infection Pafumi Carlo, Leanza Vito,
More informationHPV test results and histological follow-up results of patients with LSIL Cervical Cytology from the Largest CAP-certified laboratory in China
2436 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(13): 2436-2441. doi: 10.7150/jca.19421 HPV test results and histological follow-up results of patients with LSIL Cervical
More informationGYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital
GYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital and Bioreference Labs (Houston) Department of Pathology
More informationHUMAN PAPILLOMAVIRUS TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HUMAN PAPILLOMAVIRUS TESTING Policy Number: PDS - 016 Effective Date: October 1, 2018
More informationHKCOG GUIDELINES NUMBER 3 (revised November 2002) published by The Hong Kong College of Obstetricians and Gynaecologists
HKCOG Guidelines Guidelines on the Management of An Abnormal Cervical Smear Number 3 revised November 2002 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College of
More informationWorkshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation
Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation May Yu Director of Cytology Laboratory Service Department of Anatomical & Cellular Pathology Prince of Wales Hospital Cervical
More informationHigh-risk Human Papillomavirus Infection in Low Risk Women: Incidence, Patient Characteristics, and Clinical Meaning for Cervical Cancer
103 Ivyspring International Publisher Research Paper International Journal of Medical Sciences 2012; 9(1):103-107 High-risk Human Papillomavirus Infection in Low Risk Women: Incidence, Patient Characteristics,
More informationThe Korean Journal of Cytopathology 15 (1) : 17-27, 2004
5 The Korean Journal of Cytopathology 5 () : 7-7, / 5 / / (human papillomavirus, HPV), 6%, 5% HPV. HPV HPV. HPV HPV,,5 HPV HPV. HPV, 6 HPV. HPV HPV International Agency for Research on Cancer (IARC) HPV
More informationNew Diagnoses Need New Approaches: A Glimpse into the Near Future of Gynecologic Pathology
New Diagnoses Need New Approaches: A Glimpse into the Near Future of Gynecologic Pathology United States and Canadian Academy of Pathology 102 nd Annual Meeting Baltimore, Maryland Christina S. Kong, M.D.
More informationCervical Cancer Prevention in the 21 st Century Changing Paradigms
Cervical Cancer Prevention in the 21 st Century Changing Paradigms Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Faculty Disclosures: Teresa M.
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationSetting The setting was secondary care. The economic study was carried out in Italy.
Role of p16(ink4a) expression in identifying CIN2 or more severe lesions among HPVpositive patients referred for colposcopy after abnormal cytology Carozzi F, Cecchini S, Confortini M, Becattini V, Cariaggi
More informationp16 INK4a /Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya
Ngugi et al. Infectious Agents and Cancer (2015) 10:25 DOI 10.1186/s13027-015-0020-2 RESEARCH ARTICLE Open Access p16 INK4a /Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya
More informationSESSION J4. What's Next? Managing Abnormal PAPs in 2014
37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION J4 What's Next? Managing Abnormal PAPs in 2014 Session Description: Linda Eckert, MD Review current guidelines
More informationAbsolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women
Absolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women 2145 Philip E. Castle, Ph.D., M.P.H. 1 Sholom Wacholder, Ph.D. 1 Mark E. Sherman,
More informationASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests
ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures
More informationFocus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection
HPV infection in 2014 Papillomaviruses (HPV) are non-cultivable viruses with circular DNA. They can establish productive infections in the skin (warts) and in mucous membranes (genitals, larynx, etc.).
More informationR J M E Romanian Journal of Morphology & Embryology
Rom J Morphol Embryol 2013, 54(4):1061 1065 ORIGINAL PAPER R J M E Romanian Journal of Morphology & Embryology http://www.rjme.ro/ The triage of low-grade cytological abnormalities by the immunocytological
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationTriage of Women with Minor Cervical Lesions: Data Suggesting a Test and Treat Approach for HPV E6/E7 mrna Testing
Triage of Women with Minor Cervical Lesions: Data Suggesting a Test and Treat Approach for HPV E6/E7 mrna Testing Sveinung Wergeland Sørbye 1 *, Silje Fismen 1, Tore Gutteberg 2,3, Elin Synnøve Mortensen
More informationMolecular Triage: Partial and Extended Genotyping and More!
Molecular Triage: Partial and Extended Genotyping and More! Thomas C. Wright, Jr. MD Professor Emeritus Columbia University, New York Pathologist, Enzo Clinical Laboratories, Farmingdale, NY Disclosures
More informationThe Predictors Studies (1, 2 & 3) A comparison of tests for high grade CIN in women with abnormal smears and in a screening population
The Predictors Studies (1, 2 & 3) A comparison of tests for high grade CIN in women with abnormal smears and in a screening population Jack Cuzick L Cadman, J Austin, D Mesher, A Ahmad, L Ambroisine, L
More information(Pap) results, ie, abnormal squamous cells of undetermined significance (ASCUS). According to
The Role of Human Papillomavirus Type 16/18 Genotyping in Predicting High-Grade Cervical/Vaginal Intraepithelial Neoplasm in Women With Mildly Abnormal Papanicolaou Results Ming Guo, MD 1 ; Yun Gong, MD
More informationComparison of Diagnostic Cytomorphology of Atypical Squamous Cells in Liquid-Based Preparations and Conventional Smears
The Korean Journal of Pathology 2012; 46: 365-369 ORIGINAL ARTICLE Comparison of Diagnostic Cytomorphology of Atypical Squamous Cells in Liquid-Based Preparations and Conventional Smears Jung Dal Lee 1,2
More informationThe clearest path to the most meaningful results. The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way
The clearest path to the most meaningful results The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way The cobas HPV Test KNOW THE RISK Help guide clinical decision
More informationLong-Term Outcome and Relative Risk in Women With Atypical Squamous Cells of Undetermined Significance
Anatomic Pathology / LONG-TERM OUTCOME WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Long-Term Outcome and Relative Risk in Women With Atypical Squamous Cells of Undetermined Significance Stephen
More informationCervical Cancer 4/27/2016
Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical College of Wisconsin May 6, 2016 Cervical Cancer In US about
More informationEradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
More informationHPV Testing ASC-US. Jodie Zeke, a nurse practitioner, received initial CE2. 5. By Kim K. Choma, MSN, APN,C
CE2. 5 HOURS Continuing Education By Kim K. Choma, MSN, APN,C & ASC-US HPV Testing When the Pap result is atypical squamous cells of undetermined significance, testing for the human papillomavirus may
More informationUpdate on HPV Testing. Robert Schlaberg, M.D., Dr. med., M.P.H. Assistant Professor, University of Utah Medical Director, ARUP Laboratories
Update on HPV Testing Robert Schlaberg, M.D., Dr. med., M.P.H. Assistant Professor, University of Utah Medical Director, ARUP Laboratories Disclosures In accordance with ACCME guidelines, any individual
More informationIJC International Journal of Cancer
IJC International Journal of Cancer The clinical impact of using p16 INK4a immunochemistry in cervical histopathology and cytology: An update of recent developments Christine Bergeron 1, Guglielmo Ronco
More informationColposcopy. Attila L Major, MD, PhD
Colposcopy Attila L Major, MD, PhD Histology Colposcopy Cytology It has been estimated that annual Pap smear testing reduces a woman s chance of dying of cervical cancer from 4 in 1000 to about 5 in 10,000
More informationShould Anal Pap Smears Be a Standard of Care in HIV Management?
Should Anal Pap Smears Be a Standard of Care in HIV Management? Gordon Dickinson, M.D., FACP Professor of Medicine and Chief Infectious Diseases, Miller School of Medicine Short Answer: NO But 15-20 HPV
More informationEU guidelines for reporting gynaecological cytology
EU guidelines for reporting gynaecological cytology Amanda Herbert Guy s & St Thomas Foundation NHS Trust 5th EFCS Annual Tutorial, Trondheim, Norway 28 th May 1 st June 2012 EU guidelines aim to harmonize
More information